Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003 April 27, 2021 TORONTO–(BUSINESS WIRE)–Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003 ← Triumvira Appoints Teresa McRoberts as Chief Financial Officer and Announces Senior Level PromotionsNICE Renews Support for Use of AI-powered HeartFlow Analysis in Heart Disease Diagnosis →
